{"filing":{"accession_number":"0001567264-26-000049","cik":"0001567264","ticker":"INTS","company_name":"INTENSITY THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"intensity-20260616.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1567264/000156726426000049/intensity-20260616.htm"},"events":[{"id":11315,"run_id":9932,"accession_number":"0001567264-26-000049","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder voting results from Intensity Therapeutics' June 16, 2026 annual meeting of stockholders. The filing presents final voting tallies for five proposals: election of two Class III directors (Dr. Emer Leahy and Lewis H. Bender), ratification of EisnerAmper LLP as independent auditor, approval of amendments to the 2021 Stock Incentive Plan and 2024 Employee Stock Purchase Plan, and approval of potential adjournment. All proposals passed with majority support. This is a material event as it reflects stockholder approval of key governance and compensation matters.","company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7874,"accession_number":"0001567264-26-000049","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Intensity Therapeutics' June 16, 2026 annual meeting of stockholders. The filing presents final voting tallies for five proposals: election of two Class III directors (Dr. Emer Leahy and Lewis H. Bender), ratification of EisnerAmper LLP as independent auditor, approval of amendments to the 2021 Stock Incentive Plan and 2024 Employee Stock Purchase Plan, and approval of potential adjournment. All proposals passed with majority support. This is a material event as it reflects stockholder approval of key governance and compensation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:16:06.707514+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7874,"accession_number":"0001567264-26-000049","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Intensity Therapeutics' June 16, 2026 annual meeting of stockholders. The filing presents final voting tallies for five proposals: election of two Class III directors (Dr. Emer Leahy and Lewis H. Bender), ratification of EisnerAmper LLP as independent auditor, approval of amendments to the 2021 Stock Incentive Plan and 2024 Employee Stock Purchase Plan, and approval of potential adjournment. All proposals passed with majority support. This is a material event as it reflects stockholder approval of key governance and compensation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:16:06.707514+00:00","company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","filing_date":"2026-06-16"}]}